Highlights HBM Holdings Limited

Equities

2142

KYG4403H1002

Delayed Hong Kong S.E. Other stock markets 02:37:05 2024-05-13 EDT			5-day change	1st Jan Change
1.42 ^HKD	-3.40%		+4.41%	-26.80%

04-02	HBM Holdings Returns to Profitability in 2023	MT
03-28	HBM Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

HBM Holdings Returns to Profitability in 2023	04-02	MT
HBM Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2023	03-28	CI
Harbour BioMed Announces IND Clearance for HBM9027 in the U.S	01-23	CI
HBM to Swing to 2023 Profit	01-19	MT
HBM Holdings Limited Provides Earnings Guidance for the Year Ended 31 December 2023	01-18	CI
HBM Holdings Limited commences an Equity Buyback Plan for 76,842,891 shares, representing 10% of its issued share capital, under the authorization approved on June 8, 2023.	12-19	CI
HBM Holdings Unit Nona Biosciences Signs Licensing Deal with Seagen for Tumor Medication; Shares Fall 5%	12-15	MT
HBM Holdings Limited Announces Results of the Phase Iii Clinical Trial, Which Demonstrated That the Efficacy in the Primary and Secondary Endpoints of Batoclimab	12-01	CI
HBM Swings to Profit in H1; Shares Up 6%	23-08-29	MT
Harbour BioMed Announces US IND Clearance of Its First ADC Program HBM9033 in Solid Tumors	23-08-28	CI
HBM Holdings Limited Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-28	CI
HBM Arm Nona Expects Over $1.3 Billion from ADC Product	23-08-07	MT
HBM Holdings, Beigene Sign License Deal for Antibody-Drug Conjugate Program; HBM Shares Soar 20%	23-07-14	MT
HBM to Swing to H1 Profit Amid 45% Revenue Boost	23-07-13	MT
HBM Holdings Limited Provides Earnings Guidance for the Six Months Ended 30 June 2023	23-07-13	CI
Drug Regulator Accepts HBM's Application for Batoclimab	23-06-30	MT
National Medical Products Administration of China Accepts Biologics License Application for HBM Holdings Limited's Batoclimab for Treatment of gMG	23-06-29	CI
Harbour BioMed Announces First Patient Dosed in Phase I Study of First-In-Class Anti-B7H7 Antibody HBM1020	23-06-04	CI
Harbour BioMed Reports Results of Phase Ib Clinical Trial of Porustobart in Combination of Toripalimab in Patients with Hepatocellular Carcinoma at ASCO 2023	23-05-28	CI
Nona Biosciences, A Wholly-Owned Subsidiary of HBM Holdings Limited Enters into Collaboration Agreement with Dr. Michael S. Diamond to Develop Viral Therapeutics	23-04-18	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights HBM Holdings Limited

Equities

2142

KYG4403H1002

Highlights

Filters